Resultados de Búsqueda
It is recommended in negative pressure rooms, to use high-flow nasal oxygen (HFNO) therapy for patients with hypoxaemia associated with COVID-19, ensuring it is used with caution and strict attention ...
Evidencias COVID-19
National COVID-19 Clinical Evidence Task Force
Use the lowest flow necessary to maintain oxygen saturation ≥ 92%.
ver más ... 2020High-flow humidified oxygen should be considered when unable to maintain SaO2 ≥ 92% with standard oxygen delivery despite conventional oxygen delivery at FiO2 > 6L/min or an FiO2 0.4.
Evidencias COVID-19
National COVID-19 Clinical Evidence Task Force
High-flow nasal oxygen (HFNO) therapy is a form of respiratory support where oxygen is delivered, often in conjunction with compressed air and humidification. It delivers high flow oxygen via large diameter nasal cannula that is humidified and heated. Flow rates can be given up to 60L/min in adults and 25L/min in children with an oxygen/air blender supplying oxygen at 21-100%.
ver más ... 2020It is recommended to use single rooms or negative pressure rooms wherever possible and ensure contact, droplet and airborne precautions are in place for patients with COVID-19 receiving respiratory ...
Evidencias COVID-19
National COVID-19 Clinical Evidence Task Force
For patients with COVID-19 for whom respiratory support (HFNO/NIV) is being considered, decisions should balance likelihood of patient benefit against the risk of infection for healthcare workers. For patients with COVID-19 receiving respiratory support (HFNO/NIV) or requiring intubation, use single rooms or negative pressure rooms wherever possible and ensure contact, droplet and airborne precautions are in place.
ver más ... 2020It is recommended to administer disease-modifying treatments only in the context of randomised trials with appropriate ethical approval for people with COVID-19.
Evidencias COVID-19
National COVID-19 Clinical Evidence Task Force
The Taskforce is continually monitoring research on disease-modifying treatments. As evidence accumulates regarding the use of these treatments, the Taskforce will review and update this recommendation, including in special populations (e.g. children, pregnant women, people with immunosuppression or chronic disease).
ver más ... 2020It is not recommended to administer remdesivir for people with COVID-19, only in the context of randomised trials with appropriate ethical approval.
Evidencias COVID-19
National COVID-19 Clinical Evidence Task Force
The Taskforce is continually monitoring research on antiviral and other disease-modifying treatments. As of 30 April 2020 we identified a single randomised trial of remdesivir versus placebo (total 237 participants). On 29 April, our evidence surveillance identified a media release describing the results of an interim analysis of the Adaptive COVID-19 Treatment Trial (ACTT). We will incorporate the results of this trial into the guidelines as soon as sufficient information becomes ...
ver más ... 2020